Brief: Medigene Reports Preliminary Efficacy And Immune Monitoring Data Of Phase I Of Phase I/II Mdg1011 Trial In Blood Cancers

Medigene AG

03/02/2022 11:19

Feb 3 (Reuters) - MEDIGENE AG  MDG1k.DE :
    * REPORTS PRELIMINARY EFFICACY AND IMMUNE MONITORING DATA OF
PHASE
I OF PHASE I/II MDG1011 TRIAL IN BLOOD CANCERS
    * BASED ON ITS STRATEGIC SHIFT TO DEVELOPMENT OF TCR-T
IMMUNOTHERAPIES FOR SOLID CANCER, MEDIGENE HAS ANNOUNCED
PREVIOUSLY THAT PHASE II PART OF THIS STUDY WILL ONLY BE
CONDUCTED WITH OR BY A PARTNER; BASED ON OVERALL RESULTS FROM
PHASE I PART

Source text for Eikon:  ID:nPexrJYBFa 
Further company coverage:  MDG1k.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))